These findings suggest that SCORT‐Cas13d‐gHoxB13 can effectively and safely target the undruggable HoxB13 in metastatic prostate cancer, positioning CRISPR/Cas13d as a potential treatment. Here, HOXB13 is linked to metastatic prostate carcinoma.